Skip Ribbon Commands
Skip to main content

Novel HIV Vaccines to Elicit Protective Antibodies

Elicitation of broad and potent neutralizing antibodies has been considered to be an important, if not an essential, component of a highly effective HIV vaccine, but effort to generate such antibodies by active vaccination has been largely unsuccessful. Emerging science has identified some of the roadblocks to the development of HIV-neutralizing antibodies, while other recent evidence suggests that non-neutralizing antibodies with different effector functions may also contribute to protection.

The goal of this topic is to identify and evaluate novel and innovative HIV vaccine product concepts for the elicitation of protective antibodies, including a broad range of antibody specificities and effector functions. Research under this topic area may include the development of new technologies insofar as they are clearly needed to efficiently develop and evaluate a specific product concept.